AU2001289707A1 - Method for the detection of apoptosis by determining apoptosis-specific markers released into an extracellular medium through cellular release mechanisms - Google Patents
Method for the detection of apoptosis by determining apoptosis-specific markers released into an extracellular medium through cellular release mechanismsInfo
- Publication number
- AU2001289707A1 AU2001289707A1 AU2001289707A AU8970701A AU2001289707A1 AU 2001289707 A1 AU2001289707 A1 AU 2001289707A1 AU 2001289707 A AU2001289707 A AU 2001289707A AU 8970701 A AU8970701 A AU 8970701A AU 2001289707 A1 AU2001289707 A1 AU 2001289707A1
- Authority
- AU
- Australia
- Prior art keywords
- apoptosis
- specific markers
- extracellular
- release mechanisms
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000006907 apoptotic process Effects 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 5
- 102000016614 Autophagy-Related Protein 5 Human genes 0.000 title abstract 4
- 108010092776 Autophagy-Related Protein 5 Proteins 0.000 title abstract 4
- 230000001413 cellular effect Effects 0.000 title abstract 3
- 238000001514 detection method Methods 0.000 title abstract 3
- 230000007246 mechanism Effects 0.000 title abstract 3
- 102100030497 Cytochrome c Human genes 0.000 abstract 3
- 108010075031 Cytochromes c Proteins 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 239000006143 cell culture medium Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000002757 inflammatory effect Effects 0.000 abstract 2
- 239000002609 medium Substances 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/80—Cytochromes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/795—Porphyrin- or corrin-ring-containing peptides
- G01N2333/80—Cytochromes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/904—Oxidoreductases (1.) acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A method for the detection of apoptosis by determining presence, amount, or activity of apoptosis-specific markers released from at least one cell undergoing apoptosis into an extracellular medium through cellular release mechanisms is disclosed. The extracellular medium includes body fluids, in particular urine, inflammatory fluid, serum, liquor, or cell culture medium, wherein samples are preferably taken from humans or animals. The method can be used for the diagnosis and/or for therapy control of diseases and/or processes associated with increased apoptosis. It can also be used for therapy control of diseases associated with decreased apoptosis. Additionally, a method is disclosed for the identification of apoptosis-modulating substances, characterized in that apoptosis-specific markers released from a cell culture sample into an extracellular cell culture medium through cellular release mechanisms are determined. The invention also concerns the use of an apoptosis detection kit for determining extracellular apoptosis-specific markers. It further relates to the use of cytochrome c and/or peptides derived thereof as a medicament, pharmaceutical compositions comprising cytochrome c and/or peptides derived thereof, and optionally a pharmaceutically acceptable carrier, and the use of cytochrome c and/or peptides derived thereof, for the preparation of a medicament for the treatment of diseases with inflammatory manifestation.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00115722 | 2000-07-21 | ||
| EP00115722 | 2000-07-21 | ||
| EP00119818 | 2000-09-12 | ||
| EP00119818 | 2000-09-12 | ||
| PCT/EP2001/008389 WO2002008752A1 (en) | 2000-07-21 | 2001-07-20 | Method for the detection of apoptosis by determining apoptosis-specific markers released into an extracellular medium through cellular release mechanisms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001289707A1 true AU2001289707A1 (en) | 2002-02-05 |
Family
ID=26071195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001289707A Abandoned AU2001289707A1 (en) | 2000-07-21 | 2001-07-20 | Method for the detection of apoptosis by determining apoptosis-specific markers released into an extracellular medium through cellular release mechanisms |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20040043435A1 (en) |
| EP (1) | EP1301786B1 (en) |
| AT (1) | ATE311595T1 (en) |
| AU (1) | AU2001289707A1 (en) |
| DE (1) | DE60115453T2 (en) |
| WO (1) | WO2002008752A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001035093A1 (en) * | 1999-11-08 | 2001-05-17 | Eisai Co. Ltd. | Method of detecting cell death and detection reagent |
| GB0108143D0 (en) * | 2001-03-31 | 2001-05-23 | Univ Dundee | High-throughput screen |
| GB0329353D0 (en) * | 2003-12-19 | 2004-01-21 | Amersham Biosciences Uk Ltd | Cytochrome C protein and assay |
| FR2915393B1 (en) * | 2007-04-27 | 2012-12-14 | Vincience | PHARMACEUTICAL AND / OR COSMETIC COMPOSITION CONTAINING CYTOCHROME C ACTIVE ACTIVATOR |
| FR2915394B1 (en) * | 2007-04-27 | 2012-12-14 | Vincience | PHARMACEUTICAL AND / OR COSMETIC COMPOSITION CONTAINING PEPTIDES |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3642978A (en) * | 1969-03-05 | 1972-02-15 | Mochida Pharm Co Ltd | Process for producing stable cytochrome c preparation |
| JPS60100517A (en) * | 1983-11-08 | 1985-06-04 | Eisai Co Ltd | Radiation remedy for ulcer and method |
| JPS6339813A (en) * | 1986-08-05 | 1988-02-20 | Eisai Co Ltd | Remedy for wound |
| US5972622A (en) * | 1996-02-08 | 1999-10-26 | Desjardins; Louise | Method of detecting apoptosis using an anti-human GP46 monoclonal anti-body |
| US6048703A (en) * | 1996-11-15 | 2000-04-11 | Cephalon, Inc. | Methods for detecting cell apoptosis |
| US5928860A (en) * | 1997-02-25 | 1999-07-27 | Kloth; Sabine | Process for determining the tolerance, or toxicity of gaseous, liquid and/or viscous substances for the human or animal organism |
| EP1116029B1 (en) * | 1998-09-24 | 2007-12-26 | Promega Corporation | Apoptosis marker antibodies and methods of use |
| US6140067A (en) * | 1999-04-30 | 2000-10-31 | Mitokor | Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus |
-
2001
- 2001-07-20 US US10/312,582 patent/US20040043435A1/en not_active Abandoned
- 2001-07-20 WO PCT/EP2001/008389 patent/WO2002008752A1/en not_active Ceased
- 2001-07-20 DE DE60115453T patent/DE60115453T2/en not_active Expired - Lifetime
- 2001-07-20 AU AU2001289707A patent/AU2001289707A1/en not_active Abandoned
- 2001-07-20 EP EP01969449A patent/EP1301786B1/en not_active Expired - Lifetime
- 2001-07-20 AT AT01969449T patent/ATE311595T1/en active
-
2006
- 2006-11-13 US US11/598,199 patent/US20070243577A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002008752A1 (en) | 2002-01-31 |
| EP1301786B1 (en) | 2005-11-30 |
| DE60115453D1 (en) | 2006-01-05 |
| DE60115453T2 (en) | 2006-08-24 |
| ATE311595T1 (en) | 2005-12-15 |
| EP1301786A1 (en) | 2003-04-16 |
| US20070243577A1 (en) | 2007-10-18 |
| US20040043435A1 (en) | 2004-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004076639B1 (en) | Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus | |
| AU2001253079A1 (en) | Methods, compositions and kits for the detection and monitoring of breast cancer | |
| HK1045332A1 (en) | Compounds for therapy and diagnosis of lung cancer and methods for their use | |
| WO2001040269A3 (en) | Compositions and methods for therapy and diagnosis of breast cancer | |
| WO2001000828A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| WO2006073682A3 (en) | Diagnostic test | |
| WO2005040421A3 (en) | Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues | |
| WO2002059604A8 (en) | Diagnosis and treatment of multiple sclerosis | |
| WO2001079286A3 (en) | Compositions and methods for the therapy and diagnosis of breast cancer | |
| WO2003016464A3 (en) | Cancer specific oligosaccharide sequences and use thereof | |
| WO2001073027A3 (en) | Compositions and methods for therapy and diagnosis of colon cancer | |
| WO2003092601A3 (en) | A method for detecting lysosomal storage diseases | |
| WO2002090925A3 (en) | Polypeptides and nucleic acids associated with cancer | |
| KR20190043147A (en) | How to determine the condition of a wound | |
| AU2001289707A1 (en) | Method for the detection of apoptosis by determining apoptosis-specific markers released into an extracellular medium through cellular release mechanisms | |
| WO2001057207A3 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
| WO2002059611A3 (en) | Diagnosis and treatment of cancer using mammalian pellino polypeptides and polynucleotides | |
| KR20190080149A (en) | Biomarker composition for diagnosing susceptibility to hepatotoxicity and diagnosing method thereof | |
| WO2003014394A1 (en) | Method of evaluating biocompatibility | |
| Girard et al. | Subcutaneous phaeohyphomycosis due to Pyrenochaeta romeroi in a patient with leprosy | |
| WO2001062785A3 (en) | Protein and gene and their use for diagnosis and treatment of schizophrenia | |
| WO2001070976A3 (en) | Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer | |
| WO2007071829A3 (en) | Methods and means related to diseases | |
| WO2001049879A3 (en) | Methods for comparing gene expression levels or patterns in normal or tumor cells | |
| WO2001073031A3 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer |